Physician profile
Robert T Reddig
NPI 1538105754
$129,169.89
in general payments reported to CMS, 2019-2025
32 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $472 · 2020: $22K · 2021: $28K · 2022: $33K · 2023: $17K · 2024: $16K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Consulting Fee: $9,598 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,095 · Food and Beverage: $1,920 · Travel and Lodging: $1,405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,875.00 |
| Consulting Fee | $9,597.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,095.00 |
| Food and Beverage | $1,920.30 |
| Travel and Lodging | $1,404.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $76,537.40 | 2021-2024 | |
| Allergan, INC. | $25,688.94 | 2019-2021 | |
| Eisai INC. | $13,782.57 | 2023-2025 | |
| Pfizer INC. | $11,264.63 | 2023-2025 | |
| Lilly USA, LLC | $253.81 | 2021-2024 | Kisunla, Emgality, Reyvow |
| Ucb, INC. | $221.65 | 2019-2024 | Nayzilam, Briviact, Rystiggo |
| Teva Pharmaceuticals USA, INC. | $193.28 | 2019-2024 | Ajovy, Austedo, Austedo Xr |
| Amgen INC. | $131.78 | 2019-2023 | Aimovig |
| Jazz Pharmaceuticals INC. | $126.78 | 2019-2023 | |
| Sk Life Science, INC. | $115.54 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $109.09 | 2021 | |
| Lundbeck LLC | $81.99 | 2019-2024 | Vyepti |
| Kyowa Kirin, INC. | $76.62 | 2022-2023 | Nourianz |
| Neurocrine Biosciences, INC. | $70.32 | 2022 | |
| Argenx US, INC. | $60.72 | 2022-2023 | Vyvgart |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $58.10 | 2022-2025 | Crexont |
| Supernus Pharmaceuticals, INC. | $43.94 | 2019 | |
| Novartis Pharmaceuticals Corporation | $43.85 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $42.62 | 2019-2022 | |
| Impel Pharmaceuticals INC. | $32.68 | 2023 | Trudhesa |
| Acorda Therapeutics, INC | $28.78 | 2019 | |
| Axsome Therapeutics, INC. | $23.45 | 2023 | Sunosi |
| Alexion Pharmaceuticals, INC. | $23.26 | 2022 | |
| Portola Pharmaceuticals, LLC | $22.84 | 2019 | |
| Harmony Biosciences LLC | $21.50 | 2022 | |
| Sunovion Pharmaceuticals INC. | $19.29 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $17.51 | 2021 | |
| Promius Pharma LLC | $16.12 | 2019 | |
| Avion Pharmaceuticals | $15.98 | 2022 | |
| Medtronic USA, INC. | $15.25 | 2020 | |
| Ge Healthcare | $15.15 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Reddig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.